Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on May 20, 2022, to report significant amendments to its corporate governance documents. These changes, approved by stockholders at the May 18, 2022 Annual Meeting and effective May 19, 2022, aim to enhance shareholder rights and engagement. Key among these are the new provisions allowing stockholders to take certain actions by written consent (previously requiring unanimous consent) and lowering the threshold for stockholders to request a special meeting from 20% to 15% ownership, subject to specific requirements. These amendments to the Certificate of Incorporation and corresponding By-Laws were designed to provide shareholders with more flexibility in corporate decision-making and to facilitate greater participation in company governance. Investors should note that these changes are effective immediately and reflect the company's responsiveness to shareholder input on corporate governance matters, potentially leading to a more engaged shareholder base.
Key Highlights
- 1Stockholders approved amendments to the Restated Certificate of Incorporation at the 2022 Annual Meeting.
- 2The company now allows stockholder actions by written consent, subject to certain requirements (previously required unanimous consent).
- 3The ownership threshold for stockholders to request a special meeting has been lowered from 20% to 15%.
- 4These changes are designed to provide greater flexibility and facilitate shareholder engagement in corporate governance.
- 5The amendments to the Certificate of Incorporation were filed with the Secretary of State of Delaware on May 19, 2022, and are effective as of that date.
- 6The company's By-Laws were also amended and restated to reflect these changes, effective May 19, 2022.